AMENDMENT TO LICENSE & DEVELOPMENT AGREEMENTLicense & Development Agreement • March 26th, 2013 • Alexza Pharmaceuticals Inc. • Pharmaceutical preparations • California
This AMENDMENT TO LICENSE & DEVELOPMENT AGREEMENT (this “Amendment”) is entered into as of January 4, 2013 (the “Amendment Effective Date”), by and between ALEXZA PHARMACEUTICALS, INC., a Delaware corporation with a principal place of business at 2091 Stierlin Court, Mountain View, CA 94043 (“Alexza”), and ROYALTY PHARMA a Delaware statutory trust with a principal place of business at 110 East 59th Street, 33rd Floor, New York, NY 10022 (acquiror of CYPRESS BIOSCIENCE, INC., a Delaware corporation with a principal place of business at 4350 Executive Drive, Suite 325, San Diego, CA 92121 (“Cypress”)) (“Royalty Pharma”). Alexza and Royalty Pharma are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
